INTERNATIONAL SESSIONS WITH THE MOST RENOWNED SOCIETIES WORLDWIDE Appealing sessions on the most relevant current topics in interventional cardiology will be at the forefront of a virtual, interactive event you do not want to miss! Save the date: August 2-6, 2021 Register now for FREE Learn more about the international joint sessions featured in<a href="https://solaci.org/en/2021/07/23/solaci-caci-2021-international-sessions-with-the-most-renowned-societies-worldwide/" title="Read more" >...</a>
The Fellow’s Corner | 3rd Clinical Case: True Bifurcation Lesion: Which Strategy Should We Use?
Here is the third Fellow’s Corner clinical case to keep discussing and learning alongside the entire community of hemodynamics fellows in Latin America. In this instance, we will present a case of True Bifurcation Lesion: Which Strategy Should We Use? Content 1- Case Presentation 2- Case Resolution 3- Expert Commentary Authors: Dr. Carlos Fava (ARG)<a href="https://solaci.org/en/2021/07/05/the-fellows-corner-3rd-clinical-case-true-bifurcation-lesion-which-strategy-should-we-use/" title="Read more" >...</a>
FLOWER-MI: FFR vs. Angiography for Complete Revascularization in Infarction
Functional assessment with fractional flow reserve (FFR) was not better than conventional angiography to guide complete revascularization in patients with multivessel lesions in a setting of ST-segment elevation myocardial infarction and successful primary angioplasty. These results were published in the New England Journal of Medicine (NEJM) and presented during the American College of Cardiology (ACC)<a href="https://solaci.org/en/2021/06/07/flower-mi-ffr-vs-angiography-for-complete-revascularization-in-infarction/" title="Read more" >...</a>
New Unexpected Data on Non-Culprit Vessels in MI
Patients with acute myocardial infarction presenting lesions in multiple vessels is not associated with reduced infarct size in non-culprit lesions, even when functionally significant. Animal models suggest brief periods of ischemia in non-infarct territories (non-culprit) might protect culprit territory thanks to remote ischemic preconditioning. This pre-conditioning, according to this perspective, would reduce reperfusion injury and<a href="https://solaci.org/en/2021/05/11/new-unexpected-data-on-non-culprit-vessels-in-mi/" title="Read more" >...</a>
Lower Mortality with Rechanneling vs. Medical Therapy
We had to wait for it, but we have finally seen a benefit in hard endpoints—such as mortality—derived from rechanneling. Patients with chronic total occlusion (CTO) in whom rechanneling was used as initial strategy showed higher survival rated compared with those receiving medical therapy. As initial treatment strategy, rechanneling a CTO did not show any<a href="https://solaci.org/en/2021/04/07/lower-mortality-with-rechanneling-vs-medical-therapy/" title="Read more" >...</a>
Revascularization Is Needed Before TAVR
Disease prevalence in patients with severe aortic stenosis is highly variable: from 80% in inoperable patients to only 15% according to the most recent research including low-risk patients. Given the high mortality observed in patients with heart disease, guidelines suggest considering coronary bypass revascularization in those in need of a valve replacement. This experience with<a href="https://solaci.org/en/2021/03/08/revascularization-is-needed-before-tavr/" title="Read more" >...</a>
The Most Read Articles in Interventional Cardiology during February
01- Efficacy of AstraZeneca’s Vaccine against COVID-19 This study, published in the Lancet, looks into the vaccine resulting from the collaboration of the Oxford University and AstraZeneca, among others. Read more HERE 02- Findings on Sputnik V Vaccine Against COVID-19 The Sputnik V vaccine was developed by Gamaleya NRCEM. Similarly to the Oxford-AstraZeneca vaccine, it is based on a viral vector,<a href="https://solaci.org/en/2021/03/03/the-most-read-articles-in-interventional-cardiology-during-february/" title="Read more" >...</a>
FREEDOM with FFR: Different Outcomes?
The FREEDOM has clearly established the benefit of myocardial revascularization surgery (CABG) over percutaneous coronary intervention (PCI) in diabetic patients with multivessel disease. Coronary physiology as guideline for revascularization works best precisely in this kind of patients and its impact has never been studied in diabetics. This study, published in Circ Cardiovasc Interv, assessed the<a href="https://solaci.org/en/2021/02/17/freedom-with-ffr-different-outcomes/" title="Read more" >...</a>
AHA 2020 | Effect of Evolocumab in Complex Coronary Revascularization
Evolocumab, a PCSK9 inhibitor, has shown significant reduction of complex coronary disease requiring revascularization (be it PCI or CABG). Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors induce plaque regression and could eventually reduce the risk of coronary revascularization, especially complex revascularization. The FOURIER study randomized 27564 patients with stable CAD already on statins to evolocumab<a href="https://solaci.org/en/2020/11/25/aha-2020-effect-of-evolocumab-in-complex-coronary-revascularization/" title="Read more" >...</a>
AHA 2020 | Clopidogrel Resists as the Best Option in Elective Patients
High risk patients undergoing elective PCI treated with a more potent antiplatelet scheme (ticagrelor) vs. the classic clopidogrel do not see a benefit in protection against periprocedural events and instead see increased costs and minor bleeding rate. These are the outcomes of the ALPHEUS study presented at AHA 2020 simultaneously published in the Lancet. Ticagrelor<a href="https://solaci.org/en/2020/11/20/aha-2020-clopidogrel-resists-as-the-best-option-in-elective-patients/" title="Read more" >...</a>